Novartis | NVS - Current Liabilities


Novartis reported $32.52B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bausch Health Companies USD 4.75B 205M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Canopy Growth CAD 166.75M 8.31M Jun/2026
Corcept Therapeutics USD 177.68M 23.87M Sep/2026
Drreddys Laboratories INR 154.49B 13.08B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
J&J USD 55.46B 562M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Pacira USD 126.1M 4.08M Sep/2026
Perrigo USD 1.02B 34.4M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Phibro Animal Health USD 295.79M 20.68M Sep/2026
Prestige Brands USD 168.5M 14.7M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
Zoetis USD 2.68B 621M Sep/2026